Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Invested Capital (2016 - 2025)

Historic Invested Capital for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $45.2 billion.

  • Astrazeneca's Invested Capital fell 3644.02% to $45.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $45.2 billion, marking a year-over-year decrease of 3644.02%. This contributed to the annual value of $45.2 billion for FY2025, which is 3644.02% down from last year.
  • As of Q4 2025, Astrazeneca's Invested Capital stood at $45.2 billion, which was down 3644.02% from $39.4 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Invested Capital ranged from a high of $71.2 billion in Q4 2024 and a low of $14.6 billion during Q1 2021
  • Over the past 5 years, Astrazeneca's median Invested Capital value was $38.3 billion (recorded in 2023), while the average stood at $41.4 billion.
  • Per our database at Business Quant, Astrazeneca's Invested Capital soared by 58930.59% in 2021 and then tumbled by 3644.02% in 2025.
  • Over the past 5 years, Astrazeneca's Invested Capital (Quarter) stood at $70.1 billion in 2021, then fell by 5.39% to $66.3 billion in 2022, then increased by 2.26% to $67.8 billion in 2023, then increased by 4.98% to $71.2 billion in 2024, then tumbled by 36.44% to $45.2 billion in 2025.
  • Its Invested Capital stands at $45.2 billion for Q4 2025, versus $39.4 billion for Q3 2025 and $44.8 billion for Q2 2025.